Expert Opinion on Drug Discovery

Expert Opinion on Drug Discovery is published by Informa Healthcare and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Computational Drug Discovery Methods, Receptor Mechanisms and Signaling and Cell Image Analysis Techniques, together about 36% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)

Aims and scopeJournal metrics Editorial board Expert Opinion on Drug Discovery (1746-0441; 1746-045X) is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles in drug discovery. Expert Opinion on Drug Discovery publishes original research and review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimization at the preclinical level. Articles focus on the following key areas: Chemoinformatics Bioinformatics Assay development Novel screening technologies In vitro/in vivo models Structure-based drug design Systems biology The journal also publishes drug case histories examining the steps involved in the preclinical and clinical development of a particular drug. Please note that the journal does not publish case reports or case series. Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Reach an international clinical and medical audience alongside other key opinion leaders in your field by publishing with Expert Opinion on Drug Discovery, part of the Expert Collection brand. Authors can choose to publish gold open access in this journal. For any pre-submissions enquiries, please contact the Commissioning Editor. Read full aims and scope

From the journal's Aims & Scope

Research area (LetPub): Pharmacology & Pharmacy

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

7.44LetPub · 2026-09-13

CiteScore 2026-06

9.9LetPub · 2026-09-13

SJR 2026-06

1.29LetPub · 2026-09-13

SNIP 2026-06

1.2LetPub · 2026-09-13

h-index

50LetPub · 2026-09-13

h-index

114OpenAlex · 2026-10-01

i10-index

1,445OpenAlex · 2026-10-01

2-year mean citedness

7.19OpenAlex · 2026-10-01

Self-citation rate

1.4%LetPub · 2026-09-13

Share of gold OA articles

7.09%LetPub · 2026-09-13

Volume

Articles per year

100LetPub · 2026-09-13

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

6–12 weeksLetPub · 2026-09-13

Average acceptance (community reports)

Fairly easyLetPub · 2026-09-13

Peer review

Double anonymous peer reviewPublisher website

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

No source has fee information yet; check the journal's website.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Informa Healthcare

Country or region

ENGLAND

Language

English

Frequency

Bimonthly

Founded

2006

ISSN

1746-0441

Electronic ISSN

1746-045X

Latest issue on the website

Volume 21, Issue 9 (2026)

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗Publisher website
• Special issues ↗Publisher website